Pharmacokinetics
For evogliptin, steady-state was achieved on day 4. The mean plasma
evogliptin concentration-time curves and PK parameters were similar
between EVO and EVO+GLI (Figure 2). The GMR (90% CI) of EVO+GLI to EVO
for Cmax,ss and AUCτ,ss of evogliptin
were 1.02 (0.98 – 1.06) and 0.97 (0.95 – 1.00), respectively (Table
1). Likewise, the PK parameters of evogliptin M7 and evogliptin M8 were
similar between EVO and EVO+GLI (Table 1).
For glimepiride, the mean plasma glimepiride concentration-time curves
of GLI and EVO+GLI and the PK parameters were similar (Figure 2). The
GMR (90% CI) of EVO+GLI to GLI for Cmax,ss and
AUCτ,ss of glimepiride were 1.08 (1.01 – 1.17) and 1.08
(1.02 – 1.14), respectively (Table 2). Likewise, the PK parameters of
glimepiride M1 were similar between GLI and EVO+GLI (Table 2).